Vigil + Atezolizumab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Gynecological Cancers
Conditions
Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Trial Timeline
May 31, 2017 → May 18, 2022
NCT ID
NCT03073525About Vigil + Atezolizumab
Vigil + Atezolizumab is a phase 2 stage product being developed by Roche for Advanced Gynecological Cancers. The current trial status is completed. This product is registered under clinical trial identifier NCT03073525. Target conditions include Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Gynecological Cancers were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03073525 | Phase 2 | Completed |
Competing Products
20 competing products in Advanced Gynecological Cancers